Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Canagliflozin

Approved 20 Nov 2020OralTablet

The FDA lists this product in 9 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: CANAGLIFLOZIN 100MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA210297.

Open Drugs@FDA

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Canagliflozin
Drug class: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, Combinations of oral blood glucose lowering drugs
Group: Diabetes medicines
Route: Oral
Dosage form: Tablet
Applicant: Sandoz Inc
Status: Tentative approval
FDA approval: 20 Nov 2020
Application: ANDA210297-001
RxCUI: 1373458